Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse

Inclusion Criteria: * Histologically confirmed GBM * Clinical Target Volume between 5 and 60 cc (inclusive) * 18 to 75 years old (inclusive) * Karnofsky Performance Status ≥ 70 percent * If on steroids dose (± 4mg/day) must be stable for at least two weeks prior to screening/baseline visit. If not on steroids for two weeks prior to screening/baseline visit are allowed * Adequate hematology * Adequate renal function * Adequate liver function Exclusion Criteria: * Infratentorial tumor(s), tumor(s) that communicate with the ventricles or intraventricular disease * Bilateral non-contiguous gadolinium enhancing tumor * Diffuse disease (i.e., any satellite lesions less than 1.5 cm from anticipated location of any catheter tip or less than two satellite lesions) * Known or suspected allergy to study medication or iodine * Surgical procedure within four weeks of baseline * More than one prior chemotherapy regime or chemotherapy within four weeks (nitrosourea-based within six weeks) of baseline * Radiation therapy within four weeks of baseline * Investigational agent within last 30 days * Previous treatment with any chimeric monoclonal antibody * HIV positive * Evidence of active hepatitis